羅欣藥業(002793.SZ):子公司替戈拉生片1類新藥獲批上市
格隆匯4月13日丨羅欣藥業(002793.SZ)公佈,近日,公司下屬子公司山東羅欣藥業集團股份有限公司(簡稱“山東羅欣”)收到國家藥品監督管理局核准簽發的適應症為反流性食管炎的替戈拉生片《藥品註冊證書》。
替戈拉生片是鉀離子競爭性酸阻滯劑類藥物(Potassium-Competitive AcidBlockers,P-CAB),其抑制酸分泌的作用機制為競爭性結合壁細胞內H+/K+-ATP酶(質子泵)的鉀離子結合部位。與質子泵抑制劑(PPI)不同,P-CAB 可直接抑制H+/K+-ATP酶,而無需在強酸環境下活化。而且,無論H+/K+-ATP酶活化與否,P-CAB均可與之結合。
公司在消化領域一直具備較強的市場競爭力,該次替戈拉生片1類新藥獲批上市,體現了公司在該領域的技術優勢和佈局,豐富了產品管線和產品儲備,提升了公司核心競爭力,符合公司戰略發展需求。公司將根據市場需求情況,儘快啟動該新產品的生產和銷售,投入臨牀使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.